deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03462966

Rifaximin on Visceral Hypersensitivity

Effects of Rifaximin on Visceral Hypersensitivity in Irritable Bowel Syndrome

Sponsor: Bausch Health Americas, Inc.

Conditions Irritable Bowel Syndrome Visceral Hypersensitivity
Interventions Rifaximin
Updated 15 times since 2018 Last updated: Aug 18, 2022 Started: Jul 1, 2018 Primary completion: Nov 19, 2021 Completion: Nov 19, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

recruitment challenges

Other terminated trials from Bausch Health Americas, Inc.

More terminations from Bausch Health Americas, Inc.

Other Irritable Bowel Syndrome trials with similar outcome

Browse all Irritable Bowel Syndrome trials

This PHASE2 trial investigates Irritable Bowel Syndrome and Visceral Hypersensitivity and is currently terminated or withdrawn. Bausch Health Americas, Inc. leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Jun 2019 · 7 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Sep 2020 · 12 months · monthly snapshot~Sep 2020 – ~Dec 2020 · 3 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Sep 2022 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 10 earlier versions

  1. Jan 2022 — Sep 2022 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  2. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  4. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Sep 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  6. Sep 2019 — Sep 2020 [monthly]

    Recruiting PHASE2

  7. Jun 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  8. Nov 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Jun 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE2

  10. Mar 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bausch Health Americas, Inc.
  • Cedars-Sinai Medical Center
Data source: Cedars-Sinai Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations